BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials

Sanofi announces changes to its Executive Committee

Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia

IBL Healthcare invests in KNISS Laboratories

KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.

Venus Remedies launches its flagship R&D drug Elores in Oman

The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025

Collaborative efforts and equitable access to diagnostic prevention needed to end TB: Dr. Mandaviya

Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB

BASF, Promega and Swiss TPH collaborate to drive research for malaria control

Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control

Govt. of Arunachal, Sir Ganga Ram Hospital and Religare Enterprises sign an MoU to support the development of the state’s healthcare services

The first such initiative under the MoU will involve establishing a Centre of Excellence for Renal Sciences at the Tomo Riba Institute of Health & Medical Sciences (TRIHMS)

Lincoln Pharmaceuticals posts Q1 FY24 standalone net profit at Rs. 19.01 Cr

Yashoda Medicity, Indirapuram and Draeger India join hands to establish modular ICU setup

Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes